Personal health information is the new currency of drug development and commercialization. Novel collaborations are helping pharmaceutical and life sciences companies maximize the value of new medicines.
read full article ›Why Novartis likes outcomes-based payment for Entresto in heart failure
read full article ›Gilead Sciences recently began limiting enrollment in its Sovaldi and Harvoni patient assistance program in an attempt to pressure payors to expand their coverage criteria. The big question is how payors are likely to react.
read full article ›Payers are finally getting - and using - the tools to end uninterrupted price increases for multiple sclerosis drugs as a result of an abundance of options, greater willingness to steer prescribing choices, and the entrance of the first generic for the leading treatment in the category.
read full article ›Tools that provide transparent, comparative information about the efficacy, drawbacks and costs of a range of treatment options are helping patients, clinicians and payers choose drugs wisely. They're also forcing pharma to link price more explicitly to value.
read full article ›Turing Pharmaceuticals' decision to raise the price of a drug by 5,000% not only sparked intense questions about the rationale for high prices on new and old medicines. The controversial move by the private drugmaker, and by its now-infamous CEO, also prompted other companies to distinguish themselves by more firmly justifying how they price their medicines.
read full article ›Industry leaders like to say we should put our faith in market competition to keep drug prices in check. While this line of thinking surely has some knee-jerk appeal, drug pricing has never been governed by competition in the same way other markets are, where there is much more consumer choice.
read full article ›One of two identical Phase III trials testing the IL-13 blocker in severe asthma patients met its primary endpoint, while the other failed.
read full article ›Anthem wants out of contract – perhaps just to bring operations in-house.
read full article ›A couple weeks ago, I imagined a "dream team" of people who could break the mold and come up with a more fair, sustainable way for pricing drugs. The goal: Improve access to medicines, improve patient outcomes, and maintain profit incentives for companies to keep developing innovative new ones.
read full article ›